Which diabetes drug fights fatty liver better? new study pits dapagliflozin against empagliflozin

NCT ID NCT07363707

Completed Disease control Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 4 trial compared two common diabetes drugs, dapagliflozin and empagliflozin, added to metformin in 108 adults with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). Participants took one of the two drugs daily for six months. Researchers used liver scans and blood tests to measure changes in liver fat and function, aiming to see which drug works better for NAFLD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin and empagliflozin (SGLT2 inhibitors)
What this could lead to: If successful, this study could show which SGLT2 inhibitor is better at reducing liver fat in people with type 2 diabetes and NAFLD, potentially guiding treatment choices.
What could go wrong: This is a small, completed phase 4 trial with only 108 participants, so results may not apply to everyone. The primary outcomes are surrogate markers (liver stiffness and blood tests), not hard endpoints like liver-related illness or death.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAFLD - NONALCOHOLIC FATTY LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NAFLD - NONALCOHOLIC FATTY LIVER DISEASE

Contacts and locations

Locations

Beni Suef University Hospital

Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.